Does a human study or FDA advisory discussion mean a peptide is approved?

No. Study publication, registration, advisory discussion, compounding policy and exact-product approval are separate questions. This bounded collection records those differences; it does not recommend a peptide or represent a systematic review.

Can I save my worksheet?

Yes. Download a text file or use Print / save as PDF. Entries stay in browser memory and are not emailed or saved to your Sipra account. Clearing or reloading the page removes them from the page, while files and printouts you saved remain under your control.

Is a registered clinical study the same as a published result?

No. A registry entry can describe a planned or ongoing study without providing peer-reviewed results. Read the study status, population, intervention and result links separately. 2

Does selecting the human filter prove safety or benefit?

No. It only limits the displayed records by population. You still need to check the exact product, study design, outcome and limitations. The tool does not compare doses, recommend use or establish safety.

Explore peptide evidence and FDA sources

Sipra Editorial Team

Updated September 14, 2026 · September 14, 2026

Explore sources, not treatment rankings

A small, dated collection showing how human studies, animal experiments, trial registrations and product labels differ. It is not a systematic review.

Research population

FDA source context

4 matching source records · Sources checked 2026-09-14

CJC-1295: published human trials

Randomized placebo-controlled trials

Population: Healthy adults aged 21 to 61
Duration: 28 and 49 days
Endpoints: GH and IGF-I concentrations; pharmacokinetics
Limits: Hormone endpoints in healthy volunteers do not establish patient benefit, long-term safety or applicability to other CJC formulations.
Status history: 2006: trial publication. FDA’s current safety-risk page discusses CJC-1295 and reports serious adverse events. A paper is not product approval.

Teichman et al., 2006 (PMID 16352683) · FDA source

BPC-157: human study registration

Trial registry record

Population: Healthy adults aged 18 to 35 in the registered oral PCO-02 study
Duration: Three weeks of planned participation; registry safety time frame six months and pharmacokinetic time frame 168 hours
Endpoints: Registered adverse events and pharmacokinetic measures
Limits: A registration describes a planned study. This record was last verified in October 2015, has unknown status and has no posted results. It does not establish effectiveness.
Status history: 2015: study registration. July 23, 2026: FDA advisory meeting agenda included BPC-157-related substances for compounding discussion. Discussion or an advisory recommendation is not FDA drug approval.

ClinicalTrials.gov NCT02637284 · FDA source

CJC-1295: animal research

Animal experiment

Population: Mice with GHRH gene deletion
Duration: Five weeks
Endpoints: Growth in an experimental mouse model
Limits: Animal results cannot establish effectiveness or a regimen for people.
Status history: 2006: animal study publication. Current FDA safety discussion is separate from that experiment.

Alba et al., 2006 (PMID 16822960) · FDA source

Wegovy injection: Study 2 in the product label

FDA-approved product label

Population: Label Study 2: 1,961 adults with obesity or overweight plus a weight-related condition; type 2 diabetes excluded
Duration: 68 weeks in Study 2
Endpoints: Percentage body-weight change and proportions reaching the study’s weight-change endpoints
Limits: Approval and study findings belong to the exact labeled product and indication. They do not transfer to compounded products or other peptides.
Status history: March 2026: this label revision. Check the latest exact-product label before relying on instructions.

Wegovy prescribing information, March 2026 · FDA source

Sources checked 2026-09-14. Human research, FDA product approval and compounding policy are different questions. This collection does not recommend, rank, dose or establish eligibility for a peptide. Compounded drugs are not FDA-approved.

Read a certificate of analysis critically

A worked example

Example filter: human sources with FDA safety review or advisory discussion

Where you land: 2 source records
CJC-1295: published human trials: Randomized placebo-controlled trials. Population: Healthy adults aged 21 to 61. Duration: 28 and 49 days. Endpoints: GH and IGF-I concentrations; pharmacokinetics. Limits: Hormone endpoints in healthy volunteers do not establish patient benefit, long-term safety or applicability to other CJC formulations. Source: https://pubmed.ncbi.nlm.nih.gov/16352683/ Regulatory context: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks History: 2006: trial publication. FDA’s current safety-risk page discusses CJC-1295 and reports serious adverse events. A paper is not product approval.
BPC-157: human study registration: Trial registry record. Population: Healthy adults aged 18 to 35 in the registered oral PCO-02 study. Duration: Three weeks of planned participation; registry safety time frame six months and pharmacokinetic time frame 168 hours. Endpoints: Registered adverse events and pharmacokinetic measures. Limits: A registration describes a planned study. This record was last verified in October 2015, has unknown status and has no posted results. It does not establish effectiveness. Source: https://clinicaltrials.gov/study/NCT02637284 Regulatory context: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 History: 2015: study registration. July 23, 2026: FDA advisory meeting agenda included BPC-157-related substances for compounding discussion. Discussion or an advisory recommendation is not FDA drug approval.

A human study record and an FDA advisory discussion answer different questions; neither is a treatment recommendation.

Run your own numbers in the tool above.

Reading evidence

Start with the population and the outcome

A laboratory marker, animal experiment, registered study and clinical outcome are different kinds of evidence. This collection deliberately keeps the study type and population beside each record. It does not claim to be a complete or systematic review.

FDA approval applies to an exact product and its labeled uses. An advisory discussion, compounding policy or laboratory certificate does not give another product that approval. Compounded drugs are not FDA-approved.

A filter is not a recommendation

The filters narrow a bounded source list. They do not rank products, compare benefits, establish safety or tell you whether a substance is appropriate for human use.

Before you finish

Read each record by what it can answer

Check	What to capture
Human study	Who was studied, which product was used and which outcome was measured
Animal or laboratory work	A biological question that may not translate to people
FDA material	The exact product, regulatory question or safety concern addressed

Use the certificate-of-analysis checklist to examine a report’s limits, or browse all tools.

Frequently asked questions

Every medication on sipra is prescribed by a licensed physician, so your care always starts with a visit. Your sipra membership gives you ongoing access to those physician visits, so you can check in, adjust your plan, and ask questions whenever you need, without paying per visit. It is how we keep high-quality care convenient: one membership, physician access whenever you need it, and support at every step.

Was this helpful?

Tools

More quick checks from sipra.

GLP-1 savings calculator

Water intake calculator

Per-kilogram method

Waist-to-height ratio

WHtR method

Sleep apnea screener

STOP-BANG

GLP-1 side effect checker

When to worry

Sources

Teichman et al. CJC-1295 in healthy adults. 2006. pubmed.ncbi.nlm.nih.gov
ClinicalTrials.gov NCT02637284; study registration, not a published result. clinicaltrials.gov
Alba et al. CJC-1295 in a mouse model. 2006. pubmed.ncbi.nlm.nih.gov
FDA Wegovy prescribing information, March 2026. fda.gov
FDA July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting. fda.gov
FDA substances that may present significant safety risks. fda.gov

Educational information only. This tool does not diagnose, prescribe or confirm that a medication or product is safe. Updated September 14, 2026 by Sipra Editorial Team. Sources checked September 14, 2026.

Compounded medications are not FDA-approved and require a patient-specific prescription. Brand names are trademarks of their owners; sipra is not affiliated with them.

Explore peptide evidence and FDA sources